两种药使用中报告频率最多的不良反应是呕吐，依拉鲁肽组相比依克那肽组持续呕吐的发生要稍轻些。
Nausea was the most commonly reported adverse event with both agents, with slightly less persistent nausea in the liraglutide group than in the exenatide group.
前景 ：每周服用一次艾塞那肽所产生的非常强劲的改善血糖控制以及体重减轻的作用，必将受到糖尿病患者的欢迎。
Perspective: The impressive and very robust improved glycemic control and weight loss with once-weekly exenatide will be welcome to diabetics.
从基准到第24周C -肽曲线下面积依那西普组表现出较大变化（ 依那西普组增加39 ％与安慰剂组下降20 ％；
The etanercept group showed a greater percent change in C-peptide area under the curve from baseline to week 24 (39% increase in etanercept group versus 20% decrease in placebo group;
应用推荐